JP2008513524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513524A5 JP2008513524A5 JP2007532749A JP2007532749A JP2008513524A5 JP 2008513524 A5 JP2008513524 A5 JP 2008513524A5 JP 2007532749 A JP2007532749 A JP 2007532749A JP 2007532749 A JP2007532749 A JP 2007532749A JP 2008513524 A5 JP2008513524 A5 JP 2008513524A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- release formulation
- sustained release
- sustained
- pharmaceutically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 52
- 239000012458 free base Substances 0.000 claims description 27
- YVPUUUDAZYFFQT-UHFFFAOYSA-N 7-(4-methylpiperazin-1-yl)-3h-1,3-benzoxazol-2-one Chemical compound C1CN(C)CCN1C1=CC=CC2=C1OC(=O)N2 YVPUUUDAZYFFQT-UHFFFAOYSA-N 0.000 claims description 13
- AIBHLZVVPXCTKY-XURPUJGUSA-N (6ar,9r)-7-methyl-9-(1,2,4-triazol-1-ylmethyl)-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C([C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)C1)C)N1C=NC=N1 AIBHLZVVPXCTKY-XURPUJGUSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 8
- GDFGTRDCCWFXTG-SCTDSRPQSA-N (3r,4ar,10as)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline Chemical compound C1=CC=C2C[C@@H]3N(CCC)C[C@H](NS(=O)(=O)N(CC)CC)C[C@H]3CC2=C1O GDFGTRDCCWFXTG-SCTDSRPQSA-N 0.000 claims description 7
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 7
- KTEBZVJGMARTOQ-GCJKJVERSA-N adrogolide Chemical compound CC(=O)OC1=C(OC(C)=O)C=C2[C@H]3C(C=C(S4)CCC)=C4CN[C@@H]3CCC2=C1 KTEBZVJGMARTOQ-GCJKJVERSA-N 0.000 claims description 7
- 229950007871 adrogolide Drugs 0.000 claims description 7
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims description 7
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 claims description 6
- 229960004596 cabergoline Drugs 0.000 claims description 6
- 229960004851 pergolide Drugs 0.000 claims description 6
- 229960000924 quinagolide Drugs 0.000 claims description 6
- 229960001879 ropinirole Drugs 0.000 claims description 6
- 229960004558 terguride Drugs 0.000 claims description 6
- 229960003089 pramipexole Drugs 0.000 claims description 5
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 5
- NPEZSCRKHFTLPE-MYXGOWFTSA-N abt-431 Chemical compound Cl.CC(=O)OC1=C(OC(C)=O)C=C2[C@H]3C(C=C(S4)CCC)=C4CN[C@@H]3CCC2=C1 NPEZSCRKHFTLPE-MYXGOWFTSA-N 0.000 claims description 4
- ZQTSNGJHMUKLOM-ZDUSSCGKSA-N dinapsoline Chemical compound C1NCC2=CC=CC3=C2[C@@H]1C1=CC=C(O)C(O)=C1C3 ZQTSNGJHMUKLOM-ZDUSSCGKSA-N 0.000 claims description 3
- -1 or its transformant Chemical compound 0.000 claims description 3
- 229950011111 sumanirole Drugs 0.000 claims description 3
- RKZSNTNMEFVBDT-MRVPVSSYSA-N sumanirole Chemical compound C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 RKZSNTNMEFVBDT-MRVPVSSYSA-N 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 31
- 238000009472 formulation Methods 0.000 claims 27
- 238000013268 sustained release Methods 0.000 claims 26
- 239000012730 sustained-release form Substances 0.000 claims 26
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 11
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 10
- 239000004005 microsphere Substances 0.000 claims 10
- 229960003179 rotigotine Drugs 0.000 claims 10
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical group CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 9
- 239000003960 organic solvent Substances 0.000 claims 9
- 239000002671 adjuvant Substances 0.000 claims 8
- 239000003405 delayed action preparation Substances 0.000 claims 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- 229920002988 biodegradable polymer Polymers 0.000 claims 6
- 239000004621 biodegradable polymer Substances 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- 229960000583 acetic acid Drugs 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 229920002732 Polyanhydride Polymers 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- MNIXOHSBCFNRSH-UQGUCNKVSA-N (6ar,9r,10ar)-7-methyl-9-(1,2,4-triazol-1-ylmethyl)-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)N1C=NC=N1 MNIXOHSBCFNRSH-UQGUCNKVSA-N 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 125000005257 alkyl acyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- 125000005251 aryl acyl group Chemical group 0.000 claims 2
- 239000012362 glacial acetic acid Substances 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 150000007522 mineralic acids Chemical class 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 229920000151 polyglycol Polymers 0.000 claims 2
- 239000010695 polyglycol Substances 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 238000006116 polymerization reaction Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- 229920003169 water-soluble polymer Polymers 0.000 claims 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims 1
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229960004275 glycolic acid Drugs 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 229910052757 nitrogen Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- UQGPCEVQKLOLLM-UHFFFAOYSA-N pentaneperoxoic acid Chemical compound CCCCC(=O)OO UQGPCEVQKLOLLM-UHFFFAOYSA-N 0.000 claims 1
- 239000003208 petroleum Substances 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims 1
- 239000006104 solid solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 12
- DVLKVIJLALMCBQ-MSSRUXLCSA-N (3s,4as,10ar)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline;hydrochloride Chemical compound Cl.C1=CC=C2C[C@H]3N(CCC)C[C@@H](NS(=O)(=O)N(CC)CC)C[C@@H]3CC2=C1O DVLKVIJLALMCBQ-MSSRUXLCSA-N 0.000 description 2
- QCSYJICXNUHBML-CGCNXJRXSA-N (6ar,9r,10ar)-n-[3-(dimethylamino)propyl]-n-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 QCSYJICXNUHBML-CGCNXJRXSA-N 0.000 description 2
- XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 2
- UWCVGPLTGZWHGS-ZORIOUSZSA-N pergolide mesylate Chemical compound CS(O)(=O)=O.C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 UWCVGPLTGZWHGS-ZORIOUSZSA-N 0.000 description 2
- 229960002652 pramipexole dihydrochloride Drugs 0.000 description 2
- 229960002765 quinagolide hydrochloride Drugs 0.000 description 2
- 229960002349 ropinirole hydrochloride Drugs 0.000 description 2
- VQMNWIMYFHHFMC-UHFFFAOYSA-N tert-butyl 4-hydroxyindole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1O VQMNWIMYFHHFMC-UHFFFAOYSA-N 0.000 description 2
- NQRIKTDKFHAOKC-UHFFFAOYSA-N 7-(4-methylpiperazin-1-yl)-3h-1,3-benzoxazol-2-one;hydrochloride Chemical compound Cl.C1CN(C)CCN1C1=CC=CC2=C1OC(=O)N2 NQRIKTDKFHAOKC-UHFFFAOYSA-N 0.000 description 1
- PLUUCJAETLTLGZ-UHFFFAOYSA-N Br.I(=O)(=O)(=O)O Chemical compound Br.I(=O)(=O)(=O)O PLUUCJAETLTLGZ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- VOJRMYBBPKNLLI-ORHWHDKWSA-N sumanirole maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 VOJRMYBBPKNLLI-ORHWHDKWSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410077961 | 2004-09-21 | ||
| CN200410077961.9 | 2004-09-21 | ||
| PCT/CN2005/001521 WO2006032202A1 (fr) | 2004-09-21 | 2005-09-21 | Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008513524A JP2008513524A (ja) | 2008-05-01 |
| JP2008513524A5 true JP2008513524A5 (enExample) | 2011-04-07 |
| JP5081622B2 JP5081622B2 (ja) | 2012-11-28 |
Family
ID=36089849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532749A Expired - Lifetime JP5081622B2 (ja) | 2004-09-21 | 2005-09-21 | ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8691277B2 (enExample) |
| EP (1) | EP1797871B1 (enExample) |
| JP (1) | JP5081622B2 (enExample) |
| KR (1) | KR20070059161A (enExample) |
| AU (1) | AU2005287743B2 (enExample) |
| CA (1) | CA2581143C (enExample) |
| ES (1) | ES2536460T3 (enExample) |
| PL (1) | PL1797871T3 (enExample) |
| WO (1) | WO2006032202A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435738B2 (en) | 2003-08-18 | 2008-10-14 | Solvay Pharmaceuticals, Inc. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7405216B2 (en) | 2004-08-18 | 2008-07-29 | Solvay Pharmaceuticals, B.V. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7423040B2 (en) | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
| US7964604B2 (en) | 2005-02-18 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Bifeprunox mesylate maintenance dose compositions and methods for using the same |
| WO2007117687A2 (en) * | 2006-04-06 | 2007-10-18 | Nupathe Inc. | Implants for the treatment of dopamine associated states |
| US8106056B2 (en) | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
| US7786126B2 (en) | 2006-06-16 | 2010-08-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising SLV308 and a dopamine agonist |
| EP2035002A1 (en) * | 2006-06-16 | 2009-03-18 | Solvay Pharmaceuticals B.V. | Combination preparations comprising slv308 and a l-dopa |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| WO2008009665A1 (en) * | 2006-07-19 | 2008-01-24 | Boehringer Ingelheim International Gmbh | Treatment of pain |
| CA2725482A1 (en) * | 2008-06-09 | 2009-12-17 | Supernus Pharmaceuticals, Inc. | Controlled release formulations of pramipexole |
| WO2010035245A2 (en) | 2008-09-29 | 2010-04-01 | Wockhardt Research Centre | Extended release dosage form of ropinirole |
| FR2936710B1 (fr) * | 2008-10-07 | 2011-01-07 | Ceva Sante Animale | Composition veterinaire antiprolactinique destinee aux ruminants |
| CA2767029A1 (en) * | 2009-07-02 | 2011-01-06 | Supernus Pharmaceuticals, Inc. | A method of treatment of a neurological disorder |
| WO2011012723A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Injectable sustained release compositions comprising a pramipexole prodrug |
| EP2459225A1 (en) | 2009-07-31 | 2012-06-06 | Ascendis Pharma A/S | Carrier linked pramipexole prodrugs |
| DE102010014113A1 (de) * | 2010-04-07 | 2011-10-13 | Acino Ag | Freisetzungsverfahren für Implantate |
| CA2816288C (en) | 2010-11-25 | 2016-01-26 | Shandong Luye Pharmaceutical Co., Ltd. | Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative |
| WO2012074988A1 (en) * | 2010-12-02 | 2012-06-07 | Ratiopharm Gmbh | Rotigotine ionic liquid |
| US9956201B2 (en) | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
| WO2018096560A1 (en) | 2016-11-23 | 2018-05-31 | Cipla Limited | Long acting depot formulation for the continuous dopaminergic stimulation |
| WO2019234069A1 (en) | 2018-06-08 | 2019-12-12 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising pergolide |
| KR102212722B1 (ko) * | 2019-12-23 | 2021-02-08 | 환인제약 주식회사 | 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166800A (en) * | 1977-08-25 | 1979-09-04 | Sandoz, Inc. | Processes for preparation of microspheres |
| JP2651320B2 (ja) * | 1992-07-16 | 1997-09-10 | 田辺製薬株式会社 | 徐放性マイクロスフェア製剤の製造方法 |
| AU737078C (en) * | 1996-05-24 | 2002-05-02 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
| JPH10167968A (ja) * | 1996-10-09 | 1998-06-23 | Takeda Chem Ind Ltd | マイクロパーティクルの製造法 |
| AU4571097A (en) | 1996-10-09 | 1998-05-05 | Takeda Chemical Industries Ltd. | A method for producing a microparticle |
| AU739469B2 (en) * | 1996-12-20 | 2001-10-11 | Alza Corporation | Gel composition and methods |
| JP3663271B2 (ja) * | 1997-01-24 | 2005-06-22 | シュバルツ ファルマ アクチェンゲゼルシャフト | 新規の分枝鎖エステル及びその製法 |
| IL140899A0 (en) * | 1998-07-17 | 2002-02-10 | Skyepharma Inc | Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof |
| US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
| TR200101759T2 (tr) * | 1998-12-16 | 2001-12-21 | Aventis Pharmaceuticals Inc. | Biyolojik olarak çözünebilir polimer kapsülü içindeki serotonin alıcısı antagonisti. |
| GB9828861D0 (en) * | 1998-12-31 | 1999-02-17 | Danbiosyst Uk | Compositions |
| EP1110372B1 (en) | 1999-07-09 | 2006-09-20 | BTS Holding International B.V. | Optical scanning apparatus with switchable resolution |
| CN1190454C (zh) | 2000-04-28 | 2005-02-23 | 田边制药株式会社 | 用于制备微球的方法 |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10055742B4 (de) * | 2000-11-10 | 2006-05-11 | Schwarz Pharma Ag | Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen |
| AU2002259045B2 (en) * | 2001-04-26 | 2008-05-22 | Psivida Us Inc. | Sustained release drug delivery system containing codrugs |
| JP4987232B2 (ja) * | 2002-11-18 | 2012-07-25 | ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー | 新規のポリマーを用いた医療用デバイス |
| PL1610791T3 (pl) | 2003-03-31 | 2011-07-29 | Titan Pharmaceuticals Inc | Wszczepialne urządzenie polimerowe do przedłużonego uwalniania agonisty dopaminy |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
-
2005
- 2005-09-21 US US11/663,411 patent/US8691277B2/en active Active
- 2005-09-21 KR KR1020077008896A patent/KR20070059161A/ko not_active Ceased
- 2005-09-21 JP JP2007532749A patent/JP5081622B2/ja not_active Expired - Lifetime
- 2005-09-21 ES ES05792179.3T patent/ES2536460T3/es not_active Expired - Lifetime
- 2005-09-21 PL PL05792179T patent/PL1797871T3/pl unknown
- 2005-09-21 CA CA2581143A patent/CA2581143C/en not_active Expired - Fee Related
- 2005-09-21 AU AU2005287743A patent/AU2005287743B2/en not_active Ceased
- 2005-09-21 WO PCT/CN2005/001521 patent/WO2006032202A1/zh not_active Ceased
- 2005-09-21 EP EP05792179.3A patent/EP1797871B1/en not_active Expired - Lifetime
-
2014
- 2014-03-17 US US14/182,652 patent/US9220782B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513524A5 (enExample) | ||
| JP5081622B2 (ja) | ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法 | |
| CN100563658C (zh) | 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂 | |
| JP2013543874A5 (enExample) | ||
| EP2327397A2 (en) | Method for manufacturing sustained release microsphere by solvent flow evaporation method | |
| CN103209704A (zh) | 有机化合物 | |
| WO2014207664A2 (en) | Stable pharmaceutical composition of asenapine | |
| JP2006514923A (ja) | 注射可能な新規なデポ製剤 | |
| JP2016527308A (ja) | エンテカビル微小球及びこれを含む非経口投与用医薬組成物 | |
| TW201429507A (zh) | 包含作爲活性成分的四唑衍生物之具改良溶解度的固態分散體 | |
| KR101663561B1 (ko) | 서방출성 미립구의 제조방법 | |
| CN1762495B (zh) | 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺 | |
| CN115942935B (zh) | 包括氯胺酮的微球制剂及其制备和使用方法 | |
| KR20230036886A (ko) | 생분해성 고분자를 이용한 서방형 미립구 및 이의 제조방법 | |
| CN113226288B (zh) | 纳曲酮注射型缓释制剂 | |
| AU2022394933A1 (en) | Sustained-release injectable composition containing naltrexone and method for preparing same | |
| KR102793673B1 (ko) | 바리시티닙을 포함하는 장기지속형 미립구의 제조 방법 및 이의 제조 방법으로 제조된 바리시티닙을 포함하는 장기지속형 미립구 | |
| KR102898979B1 (ko) | 주사가능한 날트렉손 서방형 약학 제제 | |
| WO2006066509A1 (fr) | Préparation microsphérique à libération prolongée injectable de dérivés de 3,3-diphénylpropylamine servant d'antagonistes du récepteur muscarinique | |
| WO2019079095A2 (en) | COMPOSITION AND PROCESS FOR PRODUCTION OF PROLONGED RELEASE PREPARATION OF RISPERIDONE | |
| WO2025101020A1 (ko) | 패티게이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도 | |
| KR20230032772A (ko) | 아픽사반을 함유하는 서방성 미립구 | |
| HK40047988A (en) | Naltrexone injectable sustained release formulation | |
| JPWO2001005795A1 (ja) | 頻尿もしくは尿失禁の治療または予防剤 |